Abb Vie Inc. - Understand $abbv stock

$ABBV Market Cap: $311.8 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$55.53B

TTM

Gross Margin

67.17%

TTM

Net Earnings

$5.122B

TTM

Current Assets

$27.79B

Q3 2024

Current Liabilities

$43.06B

Q3 2024

Current Ratio

64.52%

Q3 2024

Total Assets

$143.4B

Q3 2024

Total Liabilities

$76.09B

Q3 2024

Book Value

$67.33B

Q3 2024

Cash

$7.257B

Q3 2024

P/E

60.88

Nov 29, 2024 EST

Free Cash Flow

$15.62B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$54.32B	$58.05B	$56.20B	$45.80B	$33.27B	$32.75B	$28.22B	$25.64B	$22.86B	$19.96B	$18.79B	$18.38B	$17.44B	$15.64B	$14.21B
YoY Change	-6.44%	3.3%	22.69%	37.69%	1.57%	16.08%	10.06%	12.16%	14.52%	6.23%	2.23%	5.37%	11.55%	10.02%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$54.32B	$58.05B	$56.20B	$45.80B	$33.27B	$32.75B	$28.22B	$25.64B	$22.86B	$19.96B	$18.79B	$18.38B	$17.44B	$15.64B	$14.21B
Cost Of Revenue	$20.42B	$17.41B	$17.45B	$15.39B	$7.439B	$7.718B	$7.042B	$5.832B	$4.500B	$4.426B	$4.581B	$4.508B	$4.639B	$4.287B	$4.056B
Gross Profit	$33.90B	$40.64B	$38.75B	$30.42B	$25.83B	$25.04B	$21.17B	$19.81B	$18.36B	$15.53B	$14.21B	$13.87B	$12.81B	$11.35B	$10.16B
Gross Profit Margin	62.42%	70.0%	68.96%	66.41%	77.64%	76.44%	75.04%	77.25%	80.31%	77.83%	75.62%	75.47%	73.41%	72.59%	71.46%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Selling, General & Admin	$12.87B	$15.26B	$12.35B	$11.30B	$6.942B	$7.399B	$6.295B	$5.881B	$6.387B	$7.724B	$5.352B	$4.989B	$5.894B	$3.805B	$3.322B
YoY Change	-15.65%	23.57%	9.29%	62.76%	-6.18%	17.54%	7.04%	-7.92%	-17.31%	44.32%	7.28%	-15.35%	54.9%	14.54%
% of Gross Profit	37.97%	37.55%	31.87%	37.15%	26.88%	29.55%	29.73%	29.69%	34.79%	49.72%	37.67%	35.96%	46.03%	33.52%	32.7%
Research & Development	$7.675B	$6.510B	$7.084B	$6.557B	$6.407B	$10.33B	$5.007B	$4.385B	$4.285B	$3.297B	$2.855B	$2.778B	$2.618B	$2.369B	$1.707B
YoY Change	17.9%	-8.1%	8.04%	2.34%	-37.97%	106.29%	14.18%	2.33%	29.97%	15.48%	2.77%	6.11%	10.51%	38.78%
% of Gross Profit	22.64%	16.02%	18.28%	21.56%	24.81%	41.26%	23.65%	22.14%	23.34%	21.22%	20.09%	20.03%	20.45%	20.87%	16.8%
Depreciation & Amortization	$752.0M	$778.0M	$803.0M	$666.0M	$464.0M	$471.0M	$425.0M	$425.0M	$417.0M	$383.0M	$388.0M	$525.0M	$508.0M	$1.184B	$697.0M
YoY Change	-3.34%	-3.11%	20.57%	43.53%	-1.49%	10.82%	0.0%	1.92%	8.88%	-1.29%	-26.1%	3.35%	-57.09%	69.87%
% of Gross Profit	2.22%	1.91%	2.07%	2.19%	1.8%	1.88%	2.01%	2.15%	2.27%	2.47%	2.73%	3.78%	3.97%	10.43%	6.86%
Operating Expenses	$20.55B	$21.77B	$19.43B	$17.86B	$13.35B	$17.73B	$11.30B	$10.27B	$10.67B	$11.02B	$8.207B	$7.767B	$8.512B	$6.174B	$5.029B
YoY Change	-5.62%	12.03%	8.83%	33.76%	-24.7%	56.86%	10.09%	-3.8%	-3.17%	34.29%	5.66%	-8.75%	37.87%	22.77%
Operating Profit	$12.76B	$18.12B	$17.92B	$11.36B	$12.98B	$6.383B	$9.545B	$9.340B	$7.537B	$3.411B	$5.664B	$5.817B	$3.620B	$5.177B	$5.129B
YoY Change	-29.59%	1.08%	57.74%	-12.48%	103.4%	-33.13%	2.19%	23.92%	120.96%	-39.78%	-2.63%	60.69%	-30.08%	0.94%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Interest Expense	$2.224B	$2.230B	$2.423B	$2.454B	$1.784B	$1.348B	$1.150B	$1.047B	$719.0M	$429.0M	$299.0M	$104.0M	$20.00M	$30.00M	-$19.00M
YoY Change	-0.27%	-7.97%	-1.26%	37.56%	32.34%	17.22%	9.84%	45.62%	67.6%	43.48%	187.5%	420.0%	-33.33%	-257.89%
% of Operating Profit	17.43%	12.31%	13.52%	21.6%	13.74%	21.12%	12.05%	11.21%	9.54%	12.58%	5.28%	1.79%	0.55%	0.58%	-0.37%
Other Income/Expense, Net	-$4.677B	-$2.448B	-$2.500B	-$5.614B	-$3.006B	$500.0M	$0.00	$0.00	$0.00	$750.0M	$1.000M	$9.000M	-$2.000M	$89.00M	$1.037B
YoY Change	91.05%	-2.08%	-55.47%	86.76%	-701.2%				-100.0%	74900.0%	-88.89%	-550.0%	-102.25%	-91.42%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Pretax Income	$6.250B	$13.48B	$12.99B	$3.398B	$8.426B	$5.197B	$7.727B	$7.884B	$6.645B	$2.369B	$5.332B	$5.725B	$3.668B	$4.835B	$5.950B
YoY Change	-53.62%	3.76%	282.25%	-59.67%	62.13%	-32.74%	-1.99%	18.65%	180.5%	-55.57%	-6.86%	56.08%	-24.14%	-18.74%
Income Tax	$1.377B	$1.632B	$1.440B	-$1.224B	$544.0M	-$490.0M	$2.418B	$1.931B	$1.501B	$595.0M	$1.204B	$450.0M	$235.0M	$658.0M	$1.314B
% Of Pretax Income	22.03%	12.11%	11.09%	-36.02%	6.46%	-9.43%	31.29%	24.49%	22.59%	25.12%	22.58%	7.86%	6.41%	13.61%	22.08%
Net Earnings	$4.863B	$11.84B	$11.54B	$4.616B	$7.882B	$5.687B	$5.309B	$5.953B	$5.144B	$1.774B	$4.128B	$5.275B	$3.433B	$4.178B	$4.637B
YoY Change	-58.91%	2.55%	150.04%	-41.44%	38.6%	7.12%	-10.82%	15.73%	189.97%	-57.03%	-21.74%	53.66%	-17.83%	-9.9%
Net Earnings / Revenue	8.95%	20.39%	20.54%	10.08%	23.69%	17.36%	18.82%	23.22%	22.5%	8.89%	21.97%	28.7%	19.68%	26.72%	32.62%
Basic Earnings Per Share	$2.73	$6.65	$6.48	$2.73	$5.30	$3.67	$3.31	$3.65	$3.15	$1.11	$2.58	$3.35	$2.18
Diluted Earnings Per Share	$2.72	$6.63	$6.45	$2.72	$5.28	$3.66	$3.30	$3.63	$3.13	$1.10	$2.56	$3.35	$2.18	$2.643M	$2.933M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash & Short-Term Investments	$12.82B	$9.229B	$9.830B	$8.479B	$39.92B	$8.061B	$9.789B	$6.423B	$8.407B	$8.374B	$9.895B	$7.976B	$653.0M	$11.00M
YoY Change	38.87%	-6.11%	15.93%	-78.76%	395.27%	-17.65%	52.41%	-23.6%	0.39%	-15.37%	24.06%	1121.44%	5836.36%
Cash & Equivalents	$12.81B	$9.201B	$9.746B	$8.449B	$39.92B	$7.289B	$9.303B	$5.100B	$8.399B	$8.348B	$9.595B	$5.901B	$27.00M	$10.00M
Short-Term Investments	$2.000M	$28.00M	$84.00M	$30.00M	$0.00	$772.0M	$486.0M	$1.323B	$8.000M	$26.00M	$300.0M	$2.075B	$626.0M	$1.000M
Other Short-Term Assets	$4.932B	$4.401B	$4.993B	$3.562B	$2.354B	$1.895B	$4.741B	$3.562B	$1.458B	$2.848B	$2.000B	$1.989B	$2.012B	$3.998B
YoY Change	12.07%	-11.86%	40.17%	51.32%	24.22%	-60.03%	33.1%	144.31%	-48.81%	42.4%	0.55%	-1.14%	-49.67%
Inventory	$4.099B	$3.579B	$3.128B	$3.310B	$1.813B	$1.605B	$1.605B	$1.444B	$1.719B	$1.124B	$1.150B	$1.091B	$872.0M	$836.0M
Prepaid Expenses
Receivables	$11.16B	$11.25B	$9.977B	$8.822B	$5.428B	$5.384B	$5.088B	$4.758B	$4.730B	$3.735B	$3.854B	$4.298B	$3.817B	$3.373B
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$949.0M	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.00B	$28.46B	$27.93B	$24.17B	$49.52B	$16.95B	$21.22B	$16.19B	$16.31B	$16.08B	$17.85B	$15.35B	$7.354B	$8.218B
YoY Change	15.95%	1.92%	15.53%	-51.18%	192.23%	-20.16%	31.11%	-0.78%	1.45%	-9.9%	16.24%	108.78%	-10.51%
Property, Plant & Equipment	$5.733B	$5.672B	$5.872B	$6.143B	$3.306B	$2.883B	$2.803B	$2.604B	$2.565B	$2.485B	$2.298B	$2.247B	$2.144B	$2.358B
YoY Change	1.08%	-3.41%	-4.41%	85.81%	14.67%	2.85%	7.64%	1.52%	3.22%	8.14%	2.27%	4.8%	-9.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$304.0M	$241.0M	$277.0M	$293.0M	$93.00M	$1.420B	$2.090B	$1.783B	$145.0M	$92.00M	$118.0M	$119.0M	$229.0M	$137.0M
YoY Change	26.14%	-13.0%	-5.46%	215.05%	-93.45%	-32.06%	17.22%	1129.66%	57.61%	-22.03%	-0.84%	-48.03%	67.15%
Other Assets	$7.769B	$4.834B	$4.122B	$3.956B	$1.944B	$1.208B	$1.326B	$1.212B	$1.149B	$1.480B	$767.0M	$835.0M	$784.0M	$533.0M
YoY Change	60.72%	17.27%	4.2%	103.5%	60.93%	-8.9%	9.41%	5.48%	-22.36%	92.96%	-8.14%	6.51%	47.09%
Total Long-Term Assets	$101.7B	$110.3B	$118.6B	$126.4B	$39.60B	$42.41B	$49.56B	$49.91B	$36.74B	$11.43B	$11.35B	$11.65B	$12.17B	$12.92B
YoY Change	-7.82%	-6.96%	-6.16%	219.2%	-6.63%	-14.44%	-0.7%	35.87%	221.34%	0.72%	-2.61%	-4.22%	-5.81%
Total Assets	$134.7B	$138.8B	$146.5B	$150.6B	$89.12B	$59.35B	$70.79B	$66.10B	$53.05B	$27.51B	$29.20B	$27.01B	$19.52B	$21.14B
YoY Change
Accounts Payable	$10.32B	$8.999B	$2.882B	$2.276B	$1.452B	$1.546B	$1.474B	$1.407B	$1.597B	$6.891B	$6.375B	$5.734B	$417.0M	$357.0M
YoY Change	14.68%	212.25%	26.63%	56.75%	-6.08%	4.88%	4.76%	-11.9%	-76.82%	8.09%	11.18%	1275.06%	16.81%
Accrued Expenses	$15.60B	$12.25B	$10.22B	$9.032B	$5.423B	$4.726B	$3.832B	$3.531B	$2.987B				$1.972B	$3.404B
YoY Change	27.26%	19.94%	13.12%	66.55%	14.75%	23.33%	8.52%	18.21%					-42.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.000M	$14.00M	$34.00M	$0.00	$3.699B	$400.0M	$377.0M	$406.0M	$425.0M	$413.0M	$1.020B	$0.00	$0.00
YoY Change	-100.0%	-92.86%	-58.82%		-100.0%	824.75%	6.1%	-7.14%	-4.47%	2.91%	-59.51%
Long-Term Debt Due	$7.191B	$4.135B	$12.48B	$8.468B	$3.753B	$1.609B	$6.015B	$25.00M	$2.025B	$4.014B	$18.00M	$22.00M	$16.00M
YoY Change	73.91%	-66.87%	47.39%	125.63%	133.25%	-73.25%	23960.0%	-98.77%	-49.55%	22200.0%	-18.18%	37.5%
Total Short-Term Liabilities	$37.84B	$29.54B	$35.19B	$28.66B	$15.59B	$17.24B	$16.64B	$9.781B	$10.89B	$11.39B	$6.879B	$6.776B	$5.897B	$3.761B
YoY Change	28.11%	-16.07%	22.79%	83.9%	-9.59%	3.59%	70.14%	-10.22%	-4.38%	65.62%	1.52%	14.91%	56.79%
Long-Term Debt	$52.19B	$59.14B	$64.19B	$77.55B	$62.98B	$35.00B	$30.95B	$36.44B	$29.24B	$10.54B	$14.29B	$14.63B	$32.00M	$0.00
YoY Change	-11.74%	-7.87%	-17.23%	23.15%	79.92%	13.08%	-15.06%	24.62%	177.47%	-26.27%	-2.31%	45618.75%
Other Long-Term Liabilities	$32.33B	$30.66B	$28.70B	$27.61B	$17.60B	$14.49B	$15.61B	$8.352B	$3.695B	$3.681B	$3.535B	$2.239B	$1.660B	$1.670B
YoY Change	5.45%	6.81%	3.96%	56.88%	21.44%	-7.15%	86.84%	126.04%	0.38%	4.13%	57.88%	34.88%	-0.6%
Total Long-Term Liabilities	$84.52B	$89.79B	$92.89B	$105.2B	$80.57B	$49.49B	$46.56B	$44.79B	$32.94B	$14.22B	$17.83B	$16.87B	$1.692B	$1.670B
YoY Change	-5.87%	-3.34%	-11.67%	30.52%	62.8%	6.3%	3.94%	36.0%	131.63%	-20.24%	5.68%	896.99%	1.32%
Total Liabilities	$124.4B	$121.6B	$131.1B	$137.5B	$97.29B	$67.80B	$65.69B	$61.46B	$49.11B	$25.77B	$24.71B	$23.65B	$7.589B	$5.432B
YoY Change	2.3%	-7.3%	-4.63%	41.32%	43.5%	3.21%	6.88%	25.17%	90.54%	4.31%	4.49%	211.57%	39.71%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Basic Shares Outstanding	1.768B shares	1.771B shares	1.770B shares	1.667B shares	1.481B shares	1.541B shares	1.596B shares	1.622B shares	1.625B shares	1.595B shares	1.589B shares	1.577B shares	1.577B shares
Diluted Shares Outstanding	1.773B shares	1.778B shares	1.777B shares	1.673B shares	1.484B shares	1.546B shares	1.603B shares	1.631B shares	1.637B shares	1.610B shares	1.604B	1.577B	1.577B shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $311.83 Billion

About AbbVie Inc.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.

Industry: Pharmaceutical Preparations Peers: AMGEN INC GILEAD SCIENCES, INC. Moderna, Inc. REGENERON PHARMACEUTICALS, INC. VERTEX PHARMACEUTICALS INC / MA